XML 36 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Instruments
6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
FAIR VALUE INSTRUMENTS

NOTE 16 — FAIR VALUE INSTRUMENTS

The carrying value of financial instruments reported in the accompanying Condensed Consolidated Balance Sheets for cash, accounts receivable, accounts payable and accrued expenses payable and other liabilities approximate fair value due to the immediate or short-term nature or maturity of these financial instruments. Based upon current borrowing rates with similar maturities, which are Level 2 fair value inputs, the carrying value of lines of credit, long-term debt, and the guaranteed purchase obligations approximate the fair value as of June 30, 2022 and December 31, 2021.

The following is a description of the valuation methodologies used for assets and liabilities measured at fair value on a recurring basis:

Contingent Consideration

The contingent consideration liability represents the fair value of the future earn-out liability that the Company may be required to pay in conjunction with the acquisitions upon the achievement of certain performance milestones. The earn-out for the acquisitions is measured at fair value in each reporting period, based on Level 3 inputs, with any change to the fair value recorded in the Condensed Consolidated Statements of Income (Loss).

The following table sets forth, by level of hierarchy, the Company’s recurring measures at fair value as of June 30, 2022 and December 31, 2021, which was presented in “Other current liabilities” and “Other liabilities” on the Condensed Consolidated Balance Sheets (amounts in millions):

 

 

June 30, 2022

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Liabilities: contingent consideration

 

$

 

 

$

 

 

$

2.9

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2021

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Liabilities: contingent consideration

 

$

 

 

$

 

 

$

2.8

 

The following is a summary of changes to Level 3 instruments as of June 30, 2022 and December 31, 2021 (amounts in millions):

 

Contingent Consideration

 

Balance, January 1, 2021

$

1.8

 

Acquisition of Ginop

 

0.9

 

Change in fair value

 

0.1

 

Balance, December 31, 2021

$

2.8

 

Changes in fair value

 

0.1

 

Balance, June 30, 2022

$

2.9